{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/REVBW"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"REVBW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"REVBW\",,,,,undefined,":{"symbol":"REVBW","market":"US","secType":"STK","nameCN":"Revelation Biosciences, Inc.","latestPrice":0.0119,"timestamp":1743105600000,"preClose":0.0121,"halted":0,"volume":6966,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Pre-Market Trading","change":-0.0002,"latestTime":"03-28 08:55:40 EDT","open":0.0111,"high":0.0119,"low":0.01,"amount":71.1347,"amplitude":0.157025,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1743168600000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":0.0105,"volumeRatio":0.5535776729660651},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"REVBW\",,,,,undefined,":{"symbol":"REVBW","floatShares":0,"roa":"-52.93%","roe":"-264.85%","lyrEps":0,"volumeRatio":0.5535776729660651,"shares":0,"dividePrice":0,"high":0.0119,"amplitude":0.157025,"preClose":0.0121,"low":0.01,"week52Low":0.004,"pbRate":"0.00","week52High":0.0413,"institutionHeld":0,"latestPrice":0.0119,"eps":0,"divideRate":0,"volume":6966,"delay":0,"ttmEps":0,"open":0.0111,"prevYearClose":0.007,"prevWeekClose":0.0127,"prevMonthClose":0.0171,"prevQuarterClose":0.007,"fiveDayClose":0.0128,"twentyDayClose":0.0168,"sixtyDayClose":0.0089},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/REVBW\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"REVBW\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2520129517","title":"Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells","url":"https://stock-news.laohu8.com/highlight/detail?id=2520129517","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520129517?lang=en_us&edition=fundamental","pubTime":"2025-03-17 18:00","pubTimestamp":1742205600,"startTime":"0","endTime":"0","summary":"– Observed response is excellent surrogate of the potential of Gemini in target indications –。In this study, human PBMCs were primed with either Gemini or placebo followed by challenge with clinically relevant promoter molecules of inflammation including high mobility box protein-1  and lipopolysaccharide  in vitro. HMGB-1 is an endogenous damage associated molecular pattern  that is generated during tissue injury  which drives the inflammatory response. LPS is an exogenous pathogen associated molecular pattern  that is generated from a bacterial infection and drives the inflammatory response associated with infection .\"These exciting results further demonstrate the game-changing potential of Gemini to attenuate the inflammatory response to clinically relevant DAMPS and PAMPS,\" said James Rolke, Chief Executive Officer of Revelation. \"We look forward to demonstrating the same protective effect in cells collected from CKD patients, which will be an excellent s","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gemini-priming-attenuates-inflammation-human-100000120.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["REVB","REVBW","BK4139"],"gpt_icon":0},{"id":"2519889594","title":"Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2519889594","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519889594?lang=en_us&edition=fundamental","pubTime":"2025-03-13 18:00","pubTimestamp":1741860000,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March 13, 2025----Revelation Biosciences, Inc.  , a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, announced today that James Rolke Revelation’s Chief Executive Officer, will participate in a fireside chat at the 37th Annual Roth Conference on Tuesday, March 18, 2025 at 10:00 a.m. PT in Dana Point, CA.Investors who wish to schedule a meeting with Revelation’s management during the conference should contact their Roth representative.Revelation Biosciences, Inc. is a clinical stage life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as a prevention for acute kidney injury, and for the treatment of chronic kidney disease.Company Contacts Mike PorterInvestor Relations Porter LeVay & Rose Inc.Email: mike@pl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/revelation-biosciences-host-fireside-chat-100000585.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4218","BK4585","BK4181","HST","BK4139","REVBW","BK4588","REVB"],"gpt_icon":0},{"id":"2517772432","title":"REVB Starts 2025 With Bright Future Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2517772432","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517772432?lang=en_us&edition=fundamental","pubTime":"2025-03-07 18:19","pubTimestamp":1741342740,"startTime":"0","endTime":"0","summary":"Revelation Biosciences  is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. Revelation has multiple product candidates in development that we believe have promising potential and are based on the biology of phosphorylated hexaacyl disaccharide  and its effect on the innate immune system. The impact of PHAD on the immune system has been studied over multiple years and has been shown to have a positive effect on the human immune system. The company’s current therapeutic candidates are all based on the active ingredient PHAD, which is a synthetic version of MPLA, that is known to stimulate TLR-4. PHAD stimulation of TLR-4 leads to the production of multiple types of cytokines and chemokines which modulate the activity of the innate and adaptive immune response. Modulated activities may include stimulation and recruitment of infection fighting immune cells, down-regulation of inflammation, and/or upregulation of ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/revb-starts-2025-bright-future-101900815.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","REVBW","REVB"],"gpt_icon":0},{"id":"2517113221","title":"Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2517113221","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517113221?lang=en_us&edition=fundamental","pubTime":"2025-03-07 05:15","pubTimestamp":1741295700,"startTime":"0","endTime":"0","summary":"SAN DIEGO, March 06, 2025----Revelation Biosciences, Inc.  , a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today reported its three and twelve months ended December 31, 2024 financial results.Announced dosing of first patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients. Announced start of its PRIME Phase 1b Clinical Study of Gemini in CKD Patients. Received net proceeds of $3.7 million from the exercise of warrants in December 2024. Gemini is an intravenously administrated, proprietary formulation of phosphorylated hexaacyl disaccharide  that reduces the damage associated with inflammation by reprograming the innate immune system to respond to stress  in an attenuated manner. Revelation has conducted multiple preclinical studies demonstrating the therapeutic potential of Gemini in the target indications. Revelation previously announced positive Phase 1 clinical data for intravenous treatment with Gemini. The primar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/revelation-biosciences-inc-announces-financial-211500476.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","REVB","REVBW"],"gpt_icon":0}],"pageSize":4,"totalPage":5,"pageCount":1,"totalSize":17}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/REVBW\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"REVBW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"REVBW\",market:\"US\",delay:false,,,undefined,":{}}}